$507.2+ Billion Personalized Cancer Medicine Market

Personalized cancer medicine is indeed revolutionizing oncology by tailoring treatments to the unique genetic makeup of each patient. This approach leverages advanced genomic technologies and bioinformatics to identify specific biomarkers driving cancer progression, enabling the development of targeted therapies that are more effective and have fewer side effects than traditional treatments.

𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/A13364

Personalized Immunotherapy for Cancer Treatment
Recent advancements in personalized immunotherapy are a testament to the progress in this field. A study published in the journal Nature led by Dr. Antoni Ribas explores using advanced technologies to stimulate the immune system to target tumors specifically. This method shows promise in targeting cancer cells while minimizing damage to healthy tissues, a significant improvement over conventional treatments like chemotherapy. The strategy involves:

Analyzing genetic mutations to understand the tumor's characteristics.
Identifying immune cells capable of targeting cancer cells.
Using CRISPR gene editing to enhance the precision and effectiveness of immune responses.
Dr. Katy Rezvani emphasizes CRISPR's role in rapidly and accurately modifying immune cells, potentially accelerating the development of effective therapies. Dr. Michel Sadelain anticipates future advancements that will further streamline these processes, making personalized cancer treatments more accessible and affordable.

Enhancing Personalized Cancer Care in Southeast Asia
Efforts to expand personalized cancer care are also underway in Southeast Asia. On June 18, 2024, Thermo Fisher Scientific, the National University Hospital, Singapore (NUH), and RNA technology company Mirxes signed a Memorandum of Understanding (MoU) to enhance genomic cancer testing in the region. This collaboration aims to develop customized next-generation sequencing (NGS) solutions to improve early cancer detection and provide personalized treatment options.

NUH's expertise in biotechnology is crucial for advancing cancer care in the region.
Thermo Fisher's rapid NGS solutions support precision medicine.
Mirxes highlights the benefits of early detection and treatment.
The NUH Diagnostic Molecular Oncology Centre already offers NGS testing for several cancers, with plans to expand these services across Southeast Asia.

FDA Approves Qiagen Companion Diagnostic for KRAZATI® in Non-Small Cell Lung Cancer
QIAGEN's therascreen® KRAS RGQ PCR kit has received FDA approval as a companion diagnostic for Mirati Therapeutics' KRAZATI® in non-small cell lung cancer (NSCLC). This approval marks a significant step in enabling doctors to identify patients with a KRAS G12C mutation, making them suitable candidates for KRAZATI® treatment.

𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠: https://www.alliedmarketresearch.com/purchase-enquiry/A13364

Jonathan Arnold, QIAGEN's Vice President of Oncology and Precision Diagnostics, highlights the test's effectiveness and affordability.
Kenna Anderes, Vice President of Translational Medicine & Companion Diagnostics at Mirati Therapeutics, emphasizes the importance of expanding access to genomic testing.
This FDA approval reinforces QIAGEN's leadership in RAS companion diagnostics and enhances its expertise in KRAS-specific biomarker testing. The kit's ability to identify the KRAS G12C mutation, present in about 13% of NSCLC cases, underscores its clinical relevance. QIAGEN continues to collaborate with over 25 companies to develop companion diagnostics that aid in cancer treatment decisions, ensuring timely access through their Day-One readiness initiative.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞: https://www.alliedmarketresearch.com/personalized-cancer-medicine-market-A13364

Pawan CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.